Henry Schein (NASDAQ:HSIC) Updates FY 2026 Earnings Guidance

Henry Schein (NASDAQ:HSIC) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 5.230-5.370 for the period, compared to the consensus earnings per share estimate of 5.310. The company issued revenue guidance of $13.6 billion-$13.8 billion, compared to the consensus revenue estimate of $13.7 billion.

Analysts Set New Price Targets

Several brokerages recently commented on HSIC. UBS Group reissued a “neutral” rating and issued a $85.00 price objective (down from $87.00) on shares of Henry Schein in a research note on Wednesday. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a research note on Wednesday. Wall Street Zen downgraded shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Henry Schein in a research note on Monday. Finally, BTIG Research began coverage on shares of Henry Schein in a research report on Thursday, April 16th. They set a “neutral” rating for the company. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $86.83.

Henry Schein Stock Down 2.6%

NASDAQ:HSIC traded down $1.91 during trading hours on Thursday, reaching $70.53. The company had a trading volume of 1,605,709 shares, compared to its average volume of 1,335,122. The company has a quick ratio of 0.76, a current ratio of 1.36 and a debt-to-equity ratio of 0.59. The firm has a market cap of $8.09 billion, a price-to-earnings ratio of 21.20, a P/E/G ratio of 2.20 and a beta of 0.82. The business’s 50-day simple moving average is $76.32 and its two-hundred day simple moving average is $75.00. Henry Schein has a twelve month low of $61.94 and a twelve month high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The business had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business’s quarterly revenue was up 6.3% on a year-over-year basis. During the same period last year, the company posted $1.15 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, equities analysts expect that Henry Schein will post 5.3 earnings per share for the current year.

Insider Activity

In other news, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $78.96, for a total transaction of $224,562.24. Following the completion of the transaction, the director directly owned 15,420 shares in the company, valued at $1,217,563.20. This trade represents a 15.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Philip A. Laskawy sold 2,844 shares of Henry Schein stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the transaction, the director owned 21,961 shares of the company’s stock, valued at $1,764,785.96. This represents a 11.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 105,911 shares of company stock valued at $8,574,982. 0.89% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Jain Global LLC grew its holdings in shares of Henry Schein by 2.0% during the third quarter. Jain Global LLC now owns 10,662 shares of the company’s stock valued at $708,000 after buying an additional 207 shares during the last quarter. Captrust Financial Advisors lifted its position in shares of Henry Schein by 3.6% during the fourth quarter. Captrust Financial Advisors now owns 6,105 shares of the company’s stock valued at $461,000 after purchasing an additional 210 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Henry Schein by 1.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after purchasing an additional 229 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Henry Schein by 3.2% during the fourth quarter. Daiwa Securities Group Inc. now owns 7,689 shares of the company’s stock valued at $581,000 after purchasing an additional 236 shares in the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. lifted its position in shares of Henry Schein by 0.8% during the third quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 32,562 shares of the company’s stock valued at $2,161,000 after purchasing an additional 260 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.